ReviewLeukemia2026
Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives.
Review in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T cell (CART) therapy has revolutionized the treatment of B cell hematological malignancies, and has lead to several FDA-approved CART products beginning in 2017. However, while CART cell therapy has improved outcomes and survival, many patients eventually relapse after treatment. Research into the reasons for patient relapse following CART cell therapy has identified multiple mechanisms of resistance. These primarily include antigen loss, poor CART cell expansion or exhaustion, and tumor- or tumor-microenvironment (TME)-mediated immunosuppression of CART cells. While methods to study and engineer CART cells to circumvent antigenic loss or to prevent exhaustion are being investigated, the development of standalone or combination CART cell therapies that target both cancer cells and immunosuppressive components of the TME are less studied. In this review, we focus on the impact of the TME on CART cell efficacy in hematological malignancies and discuss promising basic and clinical approaches that may enable CART cells to overcome TME-mediated dysfunction.
Indexed as
Identifiers
42527665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.